Nephroprotection by hypoglycemic agents: Do we have supporting data?

Journal of Clinical Medicine

Volumn 4, Issue 10, 2015, Pages 1866-1889

  Górriz, Jose Luis ^a,e,f   Nieto, Javier ^b,e   Navarro González, Juan F ^c,e   Molina, Pablo ^a   Martínez Castelao, Alberto ^d,e,f   Pallardó, Luis M ^a  

^a HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE CIUDAD REAL   (Spain)

^c HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e GEENDIAB   (Spain)

^f INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Albuminuria; Antihyperglycemic drugs; DDP4 inhibitors; Diabetes mellitus; Diabetic chronic kidney disease; Diabetic nephropathy; Glucagon like peptide agonists; Nephroprotection; SGLT2 inhibition

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FIBROBLAST GROWTH FACTOR; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SOMATOMEDIN C; SULFONYLUREA;

CELL DAMAGE; DIABETIC NEPHROPATHY; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; RENAL PROTECTION; REVIEW; UPREGULATION;

EID: 85020530779     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm4101866     Document Type: Review

References (108)

1. International Diabetes Federation. IDF Diabetes Atlas, 6th ed. Available online: http://www.idf.org/diabetesatlas (accessed on 1 June 2015).
2. Reutens, A.T.; Atkins, R.C. Epidemiology of diabetic nephropathy. Contrib Nephrol. 2011, 170, 1-7.
3. Abdel-Rahman, E.M.; Saadulla, L.; Reeves, W.B.; Awad, A.S. Therapeutic modalities in diabetic nephropathy: Standard and emerging approaches. J. Gen. Intern. Med. 2012, 27, 458-468.
4. Gaede, P.; Lund-Andersen, H.; Parving, H.H.; Pedersen, O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N. Engl. J. Med. 2008, 355, 580-591.
5. Halimi, J.M. The emerging concept of chronic kidney disease without clinical proteinuria in diabetic patients. DiabetesMeTable 2012, 38, 291-297.
6. Martinez-Castelao, A.; Navarro-Gonzalez, J.F.; Gorriz, J.L.; de Alvaro, F. The Concept and the Epidemiology of Diabetic Nephropathy Have Changed in Recent Years. J. Clin. Med. 2015, 4, 1207-1216.
7. Lim, A.K.H. Diabetic nephropathy-complications and treatment. Int. J. Nephrol. Renovasc. Dis. 2014, 7, 361-381.
8. Gaede, P.; Vedel, P.; Larsen, N.; Jensen, G.V.; Parving, H.H.; Pedersen, O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 2003, 348, 383-393. J. Clin. Med. 2015, 4 1882
9. Nathan, D.M.; Cleary, P.A.; Backlund, J.Y.; Genuth, S.M.; Lachin, J.M.; Orchard, T.J. Raskin, P. Zinman, B. Diabetes Control and Complications Trial/Epidemiology of DiabetesInterventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 2005, 353, 2643-2653.
10. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993, 329, 977-986.
11. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352, 837-853.
12. Patel, A.; MacMahon, S.; Chalmers, J.; Neal, B.; Billot, L.; Woodward, M.; Marre, M.; Cooper, M.; Glasziou, P.; Grobbee D.; et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 2008, 358, 2560-2572.
13. Ismail-Beigi, F.; Craven, T.; Banerji, M.A.; Basile, J.; Calles, J.; Cohen, R.M.; Cuddihy, R.; Cushman, W.C.; Genuth, S.; Grimm R.H.; et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial. Lancet 2010, 376, 419-430.
14. Duckworth, W.; Abraira, C.; Moritz, T.; Reda, D.; Emanuele, N.; Reaven, P.D.; Zieve, F.J.; Marks, J.; Davis, S.N.; Hayward, R.; Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 2009, 360, 129-139.
15. Pilz, S.; Rutters, F.; Nijpels, G.; Stehouwer, C.D.; H0jlund, K.; Nolan, J.J.; Balkau, B.; Dekker, J.M.; RISC Investigators. Insulin sensitivity and albuminuria: The RISC study. Diabetes Care 2014, 37, 1597-1603.
16. McCormack, J.; Johns, K. Metformin’s contraindications should be contraindicated. CMAJ 2005, 173, 502-504.
17. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352, 854-856.
18. Eurich, D.T.; McAlister, F.A.; Blackburn, D.F.; Majumdar, S.R.; Tsuyuki, R.T.; Varney, J.; Johnson, J.A. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: A systematic review. BMJ 2007, 335, 497-501.
19. Rosen, P.; Wiernsperger, N.F. Metformin delays the manifestation of diabetes and vascular dysfunction in Goto-Kakizaki rats by reduction of mitochondrial oxidative stress. Diabetes Metab. Res. Rev. 2006, 22, 323-330.
20. Morales, A.I.; Detaille, D.; Prieto, M.; Puente, A.; Briones, E.; Arevalo, M.; Leverve, X.; López-Novoa, J.M.; El-Mir, M.Y. Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway. Kidney Int. 2010, 77, 861-869.
21. Rafieian-Kopaie, M. Metformin and renal injury protection. J. RenalInj. Prev. 2013, 2, 91-92.
22. Kim, J.; Shon, E.; Kim, C.S.; Kim, J.S. Renal podocyte injury in a rat model of type 2 diabetes is prevented by metformin. Exp. Diabetes Res. 2012, 2012, 210821, doi:10.1155/2012/210821. J. Clin. Med. 2015, 4 1883
23. Ke, J.T.; Li, M.; Xu, S.Q.; Zhang, W.J.; Jiang, Y.W.; Cheng, L.Y.; Lou, J.N.; Wu, W. Gliquidone decreases urinary protein by promoting tubular reabsorption in diabetic Goto-Kakizaki rats. J. Endocrinol. 2014, 220, 129-141.
24. Lachin, J.M.; Viberti, G.; Zinman, B.; Haffner, S.M.; Aftring, R.P.; Paul, G.; Kravitz, B.G. Herman, W.H. Holman,R.R. Kahn, S.E. ADOPT Study Group Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clin. J. Am. Soc. Nephrol. 2011, 6, 1032-1040.
25. Zoungas, S.; de Galan, B.E.; Ninomiya, T.; Grobbee, D.; Hamet, P.; Heller, S.; MacMahon, S.; Marre, M.; Neal, B.; Patel, A.; Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes Care 2009, 32, 2068-2074.
26. McCarty, M.F.; DiNicolantonio, J.J. Acarbose, lente carbohydrate, and prebiotics promote metabolic health and longevity by stimulating intestinal production of GLP-1. Open Heart 2015, 2, e000205, doi:10.1136/openhrt-2014-000205.
27. Holman, R.R.; Cull, C.A.; Turner, R.C. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes Care 1999, 22, 960-964.
28. Pistrosch, F.; Herbrig, K.; Kindel, B.; Passauer, J.; Fischer, S.; Gross, P. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 2005, 54, 2206-2211.
29. Buckingham, R.E.; Al-Barazanji, K.A.; Toseland, C.D.; Slaughter, M.; Connor, S.C.; West, A.; Bond, B.; Turner, N.C.; Clapham, J.C. Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 1998, 47, 1326-1334.
30. Yoshimoto, T.; Naruse, M.; Nishikawa, M.; Naruse, K.; Tanabe, A.; Seki, T.; Imaki, T.; Demura, R.; Aikawa, E.; Demura, H. Antihypertensive and vasculo and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am. J. Physiol. 1997, 272, 989-996.
31. Lee, E.Y.; Kim, G.T.; Hyun, M.; Kim, S.; Seok, S.; Choi, R.; Lee, M.Y.; Chung, C.H. Peroxisome proliferator-activated receptor-8 activation ameliorates albuminuria by preventing nephrin loss and restoring podocyte integrity in type 2 diabetes. Nephrol. Dial. Transplant. 2012, 27, 4069-4079.
32. Sarafidis, P.A.; Bakris, G.L. Protection of the kidney by thiazolidinediones: An assessment from bench to bedside. Kidney Int. 2006, 70, 1223-1233.
33. Nakamura, T.; Ushiyama, C.; Shimada, N.; Hayashi, K.; Ebihara, I.; Koide, H. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. J. Diabetes Complicat. 2000, 14, 250-254.
34. Bakris, G.; Viberti, G.; Weston, W.M.; Heise, M.; Porter, L.E.; Freed, M.I. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J. Hum. Hypertens. 2003, 17, 7-12.
35. Miyazaki, Y.; Cersosimo, E.; Triplitt, C.; DeFronzo, R.A. Rosiglitazone decreases albuminuria in type 2 diabetic patients. Kidney Int. 2007, 72, 1367-1373.
36. Agarwal, R.; Saha, C.; Battiwala, M.; Vasavada, N.; Curley, T.; Chase, S.D.; Sachs, N.; Semret, M.H. A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy. Kidney Int. 2005, 68, 285-292. J. Clin. Med. 2015, 4 1884
37. De Cosmo, S.; Prudente, S.; Lamacchia, O.; Lapice, E.; Morini, E.; Di Paola, R.; Copetti, M.; Ruggenenti, P.; Remuzzi, G.; Vaccaro O.; et al. V PPARy2 P12A polymorphism and albuminuria in patients with type 2 diabetes: A meta-analysis of case-control studies. Nephrol. Dial. Transplant. 2011, 26, 4011-4016.
38. Lapice, E.; Monticelli, A.; Cocozza, S.; Pinelli, M.; Cocozza, S.; Bruzzese, D.; Riccardi, G.; Vaccaro, O. The PPARy2 Pro12Ala variant is protective against progression of ephropathy in people with type 2 diabetes. J. Transl. Med. 2015, doi:10.1186/s12967-015-0448-6.
39. Nissen, T.E.; Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 2007, 356, 2457-2471.
40. Lincoff, A.M.; Wolski, K.; Nicholls, S.J.; Nissen, S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials. JAMA 2007, 298, 1180-1188.
41. Lewis, J.D.; Habel, L.A.; Quesenberry, C.P.; Strom, B.L.; Peng, T.; Hedderson, M.M.; Ehrlich, S.F.; Mamtani, R.; Bilker, W.; Vaughn, D.J.; et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA 2015, 314, 265-277.
42. Ferwana, M.; Firwana, B.; Hasan, R.; Al-Mallah, M.H.; Kim, S.; Montori, V.M.; Murad, M.H. Pioglitazone and risk of bladder cancer: A meta-analysis of controlled studies. DiabetMed. 2013, 30, 1026-1032.
43. Tomkin, G.H. Treatment of type 2 diabetes, lifestyle, GLP-1 agonists and DPP4 inhibitors. World J. Diabetes 2014, 5, 636-650.
44. Bullock, B.P.; Heller, R.S.; Habener, J.F. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996, 137, 2968-2978.
45. Wei, Y.; Mojsov, S. Distribution of GLP-1 and PACAP receptors in human tissues. Acta Physiol. Scand. 1996, 157, 355-357.
46. Muskiet, M.H.; Smits, M.M.; Morsink, L.M.; Diamant, M. The gut-renal axis: Do ncretin-based agents confer renoprotection in diabetes? Nat. Rev. Nephrol. 2014, 10, 88-103.
47. Tanaka, T.; Higashijima, Y.; Wada, Y.; Nangaku, M. The potential for renoprotection with incretin-based drugs. Kidney Int. 2014, 86, 701-711
48. Kórner, M.; Stóckli, M.; Waser, B.; Reubi, J.C. GLP-1 receptor expression in human tumors and human normal tissues: Potential for in vivo targeting. J. Nucl. Med. 2007, 48, 736-743.
49. Sun, A.L.; Deng, J.T.; Guan, G.J.; Chen, S.H.; Liu, Y.T.; Cheng, J.; Li, Z.W.; Zhuang, X.H.; Sun, F.D.; Deng, H.P. Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney disease. Diab. Vasc. Dis. Res. 2012, 4, 301-308.
50. Hocher, B.; Reichetzeder, C.; Alter, M.L. Renal and cardiac effects of DPP4 inhibitors-from preclinical development to clinical research. Kidney Blood Press. Res. 2012, 36, 65-84.
51. Mima, A.; Hiraoka-Yamomoto, J.; Li, Q.; Kitada, M.; Li, C.; Geraldes, P.; Matsumoto, M.; Mizutani, K.; Park, K.; Cahill, C.; Nishikawa, S.; Rask-Madsen, C.;. Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKC? Activation in diabetes. Diabetes 2012, 61, 2967-2979.
52. Schlatter, P.; Beglinger, C.; Drewe, J.; Gutmann, H. Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul. Pept. 2007, 141, 120-128.
53. Kettmann, U.; Humbel, B.; Holzhausen, H.J. Ultrastructural localization of dipeptidylpeptidase IV in the glomerulum of the rat kidney. Acta Histochem. 1992, 92, 225-227.
54. Mega, C.; de Lemos, E.T.; Vala, H.; Fernandes, R.; Oliveira, J.; Mascarenhas-Melo, F.; Teixeira, F.; Reis, F. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Exp. Diabetes Res. 2011, 2011, 162092, doi:10.1155/2011/162092.
55. Liu, W.J.; Xie, S.H.; Liu, Y.N.; Kim, V.; Hin, H.Y.; Park, S.K.; Shao, Y.M.; Park, T.S. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J. Pharmacol. Exp. Ther. 2012, 340, 248-255.
56. Alter, M.L.; Ott, I.M.; von Websky, K.; Tsuprykov, O.; Sharkovska, Y.; Krause-Relle, K.; Raila, J.; Henze, A.; Klein, T.; Hocher, B. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney Blood Press. Res. 2012, 36, 119-130.
57. Weisman, M.I.; Caiolfa, V.R.; Parola, A.H. Adenosine deaminase-complexing protein from bovine kidney. Isolation of two distinct subunits. J. Biol. Chem. 1988, 263, 5266-5270.
58. Avogaro, A.; Fadini, G.P. The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications. Diabetes Care 2014, 37, 2884-2894.
59. Li, J.; Guan, M.; Li, C.; Lyv, F.; Zeng, Y.; Zheng, Z.; Wang, C.; Xue, Y. The dipeptidyl peptidase-4 inhibitor sitagliptin protects against dyslipidemia-related kidney injury in Apolipoprotein E knockout mice. Int. J. Mol. Sci. 2014, 15, 11416-11434.
60. Marques, C.; Mega, C.; Gon9alves, A.; Rodrigues-Santos, P.; Teixeira-Lemos, E.; Teixeira, F.; Fontes-Ribeiro, C.; Reis, F.; Fernandes, R. Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals. Mediat. Inflamm. 2014, 2014, 538737, doi:10.1155/2014/538737.
61. Vaghasiya, J.; Sheth, N.; Bhalodia, Y.; Manek, R. Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes. Regul. Pept. 2011, 166, 48-54.
62. Nakashima, S.; Matsui, T.; Takeuchi, M.; Yamagishi, S.I. Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis. Horm. Metab. Res. 2014, 46, 717-721.
63. Vavrinec, P.; Henning, R.H.; Landheer, S.W.; Wang, Y.; Deelman, L.E.; Dokkum, R.P.; Buikema, H. Vildagliptin restores renal myogenic function and attenuates renal sclerosis independently of effects on blood glucose or proteinuria in Zucker diabetic fatty rat. Curr. Vasc. Pharmacol. 2014, 12, 836-844.
64. Mentlein, R. Dipeptidyl-peptidase IV (CD26)—Role in the inactivation of regulatory peptides. Regul. Pept. 1999, 85, 9-24.
65. Hattori, S. Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr. J. 2011, 58, 69-73.
66. Sakata, K.; Hayakawa, M.; Yano, Y.; Tamaki, N.; Yokota, N.; Eto, T.; Watanabe, R.; Hirayama, N.; Matsuo, T.; Kuroki, K.; et al. Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product receptor for advanced glycation end product axis, and albuminuria in Japanese type 2 diabetes. Diabetes Metab. Res. Rev. 2013, 29, 624-630. J. Clin. Med. 2015, 4 1886
67. Groop, P.-H.; Cooper, M.E.; Perkovic, V.; Emser, A.; Woerle, H.J.; von Eynatten, M. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care 2013, 36, 3460-3468.
68. Zhang, H.; Zhang, X.; Hu, C.; Lu, W. Exenatide reduces urinary transforming growth factor-P1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria. Kidney Blood Press. Res. 2012, 35, 483-488.
69. Scirica, B.M.; Bhatt, D.L.; Braunwald, E.; Steg, P.G.; Davidson, J.; Hirshberg, B.; Ohman, P.; Frederich, R.; Wiviott, S.D.; Hoffman, E.B.; Cavender, M.A.; et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 2013, 369, 1317-1326.
70. Cooper, M.E.; Perkovic, V.; McGill, J.B.; Groop, P.H.; Wanner, C.; Rosenstock, J.; Hehnke, U.; Woerle, H.J.; Eynatten, M. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data from a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes. Am. J. Kidney Dis. 2015, in press.
71. European Medicines Agency Press Office. European Medicines Agency Recommends Suspension of Avandia, Avandamet and Avaglim. Anti-Diabetes Medication to be Taken off the Market. Available online: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/09/WC500096996.pdf (accessed on 10 December 2010).
72. White, W.B.; Cannon, C.P.; Heller, S.R.; Nissen, S.E.; Bergenstal, R.M.; Bakris, G.L.; Perez, A.T.; Fleck, P.R.; Mehta, C.R.; Kupfer, S.; et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med. 2013, 369, 1327-1335.
73. Kodera, R.; Shikata, K.; Kataoka, H.U.; Takatsuka, T.; Miyamoto, S.; Sasaki, M.; Kajitani, N.; Nishishita, S.; Sarai, K.; Hirota, D.;. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 2011, 54, 965-978.
74. Park, C.W.; Kim, H.W.; Ko, S.H.; Lim, J.H.; Ryu, G.R.; Chung, H.W.; Han, S.W.; Shin, S.J.; Bang, B.K.; Breyer, M.D.;. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J. Am. Soc. Nephrol. 2007, 18, 1227-1238.
75. Yu, M.; Moreno, C.; Hoagland, K.M.; Dahly, A.; Ditter, K.; Mistry, M.; Roman, R.J. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J. Hypertens. 2003, 21, 1125-1135.
76. Crajoinas, R.O.; Oricchio, F.T.; Pessoa, T.D.; Pacheco, B.P.; Lessa, L.M.; Malnic, G.; Girardi, A.C. Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am. J. Physiol. Renal Physiol. 2011, 301, F355-F363.
77. Gutzwiller, J.P.; Tschopp, S.; Bock, A.; Zehnder, C.E.; Huber, A.R.; Kreyenbuehl, M.;
78. et al.Gutmann, H.; Drewe, J.; Henzen, C.; Goeke, B.; Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J. Clin. Endocrinol. Metab. 2004, 89, 30553061.
79. Vilsb0ll, T.; Christensen, M.; Junker, A.E.; Knop, F.K.; Gluud, L.L. Effects of glucagon-like peptide-1 receptor agonists on weight loss: Systematic review and meta-analyses of randomised controlled trials. BMJ 2012, 344, d7771, doi:10.1136/bmj.d7771. J. Clin. Med. 2015, 4 1887
80. Kim, M.; Platt, M.J.; Shibasaki, T.; Quaggin, S.E.; Backx, P.H.; Seino, S.; Simpson, J.A.; Drucker, D.J. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat. Med. 2013, 19, 67-575.
81. Dai, Y.; Mehta, J.L.; Chen, M. Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-KB Activation. Cardiovasc. Drugs Ther. 2013, 27, 371-380.
82. Jensen, E.P.; Poulsen, S.S.; Kissow, H.; Holstein-Rathlou, N.H.; Deacon, C.F.; Jensen, B.L.; Holst, J.J.; Sorensen, C.M. Activation of GLP-1 receptors on vascular smooth muscle cells reduces the autoregulatory response in afferent arterioles and increases renal blood flow. Am. J. Physiol. Renal Physiol. 2015, 308, F867-F877.
83. Thomson, S.C.; Kashkouli, A.; Singh, P. Glucagon-like peptide-1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat. Am. J. Physiol. Renal Physiol. 2013, 304, F137-F144.
84. Best, J.H.; Hoogwerf, B.J.; Herman, W.H.; Pelletier, E.M.; Smith, D.B.; Wenten, M. Hussein, M.A. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: A retrospective analysis of the LifeLink database. Diabetes Care 2011, 34, 90-95.
85. Anagnostis, P.; Athyros, V.G.; Adamidou, F.; Panagiotou, A.; Kita, M.; Karagiannis, A.; Mikhailidis, D.P. Glucagon-like peptide-1-based therapies and cardiovascular disease: Looking beyond glycaemic control. Diabetes Obes. MeTable 2011, 13, 302-312.
86. Panchapakesan, U.; Mather, A.; Pollock, C. Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease. Clin. Sci. (Lond.) 2013, 124, 17-26.
87. Thomas, M.C. Renal effects of dapagliflozin in patients with type 2 diabetes. Ther. Adv. Endocrinol. Metab. 2014, 5, 53-61.
88. Vallon, V. Tubuloglomerular feedback and the control of glomerular filtration rate. News Physiol. Sci. 2003, 18, 169-174.
89. Gilbert, R.E. Sodium-glucose linked transporter-2 inhibitors: Potential for renoprotection beyond blood glucose lowering? Kidney Int. 2014, 86, 693-700.
90. De Nicola, L.; Gabbai, F.B.; Liberti, M.E.; Sagliocca, A.; Conte, G.; Minutolo, R. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: Targeting the renal tubule in diabetes. Am. J. Kidney Dis. 2014, 64, 16-24.
91. Scheen, A. Evaluating SGLT2 inhibitors for type 2 diabetes: Pharmacokinetic and toxicological considerations. Expert Opin. Drug Metab. Toxicol. 2014, 10, 647-663.
92. Filippatos, T.D.; Liberopoulos, E.N.; Elisaf, M.S. Dapagliflozin in patients with type 2 diabetes mellitus. Ther. Adv. Endocrinol. MeTable 2015, 6, 29-41.
93. Terami, N.; Ogawa, D.; Tachibana, H.; Hatanaka, T.; Wada, J.; Nakatsuka, A.; Eguchi, J.; Horiguchi, C.S.; Nishii, N.; Yamada, H. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS ONE 2014, 9, e100777. J. Clin. Med. 2015, 4 1888
94. Vallon, V.; Rose, M.; Gerasimova, M.; Satriano, J.; Platt, K.; Koepsell, H.; Cunard, R.; Sharma, K.; Thomson, S.C.; Rieg, T. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am. J. Physiol. Renal Physiol. 2013, 304, F156-F167.
95. Thomson, S.; Rieg, T.; Miracle, C.; Mansoury, H.; Whaley, J.; Vallon, V.; Singh, P. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2012, 302, R75-R83.
96. Kojima, N.; Williams, J.; Takahashi, T.; Miyata, N.; Roman, R.J. Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats. J. Pharmacol. Exp. Ther. 2013, 345, 464-472.
97. Malatiali, S.; Francis, I.; Barac-Nieto, M. Phlorizin prevents glomerular hyperfiltration but not hypertrophy in diabetic rats. Exp. Diabetes Res. 2008, 2008, 305403, doi:10.1155/2008/305403.
98. Vallon, V.; Gerasimova, M.; Rose, M.; Masuda, T.; Satriano, J.; Mayoux, E.; Koepsell, H.; Thomson, S.C.; Rieg, T. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic akita mice. Am. J. Physiol. Renal Physiol. 2014, 306, F194-F204.
99. Gembardt, F.; Bartaun, C.; Jarzebska, N.; Mayoux, E.; Todorov, V.T.; Hohenstein, B.; Hugo, C. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension. Am. J. Physiol. Renal Physiol. 2014, 307, F317-F325.
100. Kohan, D.E.; Fioretto, P.; Tang, W.; List, F. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014, 85, 962-971.
101. Barnett, A.H.; Mithal, A.; Manassie, J.; Jones, R.; Rattunde, H.; Woerle, H.J.; Broedl, U.C. EMPA-REG RENAL trial investigators. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: A randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014, 2, 369-384.
102. Yale, J.F.; Bakris, G.; Cariou, B.; Yue, D.; David-Neto, E.; Xi, L.; Figueroa, K.; Wajs, E.; Usiskin, K.; Meininger, G. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes. Metab. 2013, 15, 463-473.
103. Cefalu, W.T.; Leiter, L.A.; Yoon, K.H.; Arias, P.; Niskanen, L.; Xie, J.; Balis, D.A.; Canovatchel, W.; Meininger, G. Efficacy and safety of canagliflozin vs. glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, doubleblind, phase 3 noninferiority trial. Lancet 2013, 382, 941-950.
104. List, J.F.; Woo, V.; Morales, E.; Tang, W.; Fiedorek, F.T. Sodium glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009, 32, 650-657.
105. Wilding, J.; Woo, V.; Soler, N.G.; Pahor, A.; Sugg, J.; Rohwedder, K.; Parikh, S.; Dapagliflozin 006 Study Group. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin. Ann. Intern. Med. 2012, 156, 405-415.
106. Fujita, Y.; Inagaki, N. Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action. J. Diabetes Investig. 2014, 5, 265-275. J. Clin. Med. 2015, 4 1889
107. Zinman, B.; Wanner, C.; Lachin, J.M.; Fitchett, D.; Bluhmki, E.; Hantel, S.; Mattheus, M.; Devins, T.; Johansen, O.R.; Woerle H.J.; et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New Engl. J. Med. 2015, doi:10.1056/NEJMoa1504720
108. Zanoli, L.; Granata, A.; Lentini, P.; Rastelli, S.; Fatuzzo, P.; Rapisarda, F.; Castellino, P. Sodium-glucose linked transporter-2 inhibitors in chronic kidney disease. Sci. World J. 2015, 2015, 317507, doi: 10.1155/2015/317507.